Guardant Health sues rival Natera over cancer-testing trade secrets
Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Guardant Health Leads the Way in Blood-Based Single Cancer Screening
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.